EUVIMEDEUVIMED entdecken
Crossref

Acetylcholinesterase Inhibitory Potential and ADMET Analysis and Molecular Docking Studies of Coumarin and Benzohydrazide Derivatives in Alzheimer’s Disease

Naveed Muhammad, Sehrish Rehman, Abdur Rauf, Umer Rashid, Muhammad Umer Khan, Fariha Javaid, Arif Lodhi, Maha Munir, Haroon Khan, Yahya S. Al-Awthan, Omar S. Bahattab, Muhammad Saleem und 2 weitere

Journal of Computational Biophysics and Chemistry · 08.08.2026 · 1-18

DOI: 10.1142/s2737416526501036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Computational Biophysics and Chemistry, online erschienen am 08.08.2026. Verfasst von Naveed Muhammad und 13 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD), a prevalent type of dementia, is an irreversible, progressive, neurodegenerative, age-related brain disease. It can be fatal and is characterized by acute behavioral abnormalities, including a decline in memory and cognitive abilities. AD is closely linked to acetylcholinesterase (AChEs), which degrades acetylcholine (ACh). By inhibiting AChE, the synaptic acetylcholine (ACh) level in the brain increases, reducing the symptoms of AD. Identifying more potent natural AChEIs is crucial for preventing the effects of AD. In this study, 28 coumarin and five benzohydrazide derivatives were examined against AChE using the microplate assay technique. The findings showed that, in comparison to the reference drug (IC[Formula: see text]M), two coumarin derivatives, compounds (CMP) 9 and 22, were effective inhibitors of AChE, with IC[Formula: see text] values of 354 ± 0.125 [Formula: see text]M and 430 ± 0.01 [Formula: see text]M, respectively. The two strong coumarin derivatives were subjected to molecular docking and ADMET analysis against human acetylcholinesterase, and CMP 9 and 22 showed excellent binding affinities with minimal energy values (−13 and − 11.4 kcal/mol). The two strong derivatives, CMP 9 and 22, are promising leads in the quest for effective AD medications because of their significant interactions with key residues in the AChE active site. Furthermore, animal model- and cell line-based verification is necessary to identify the long-term efficacy of these lead compounds.

Zitieren

APA

Muhammad, N., Rehman, S., Rauf, A., Rashid, U., Khan, M. U., Javaid, F., Lodhi, A., Munir, M., Khan, H., Al-Awthan, Y. S., Bahattab, O. S., Saleem, M., Goud, P., & Thiruvengadam, M. (2026). Acetylcholinesterase Inhibitory Potential and ADMET Analysis and Molecular Docking Studies of Coumarin and Benzohydrazide Derivatives in Alzheimer’s Disease. Journal of Computational Biophysics and Chemistry, 1-18. https://doi.org/10.1142/s2737416526501036

Vancouver

Muhammad N, Rehman S, Rauf A, Rashid U, Khan MU, Javaid F, et al. Acetylcholinesterase Inhibitory Potential and ADMET Analysis and Molecular Docking Studies of Coumarin and Benzohydrazide Derivatives in Alzheimer’s Disease. Journal of Computational Biophysics and Chemistry. 2026:1-18. doi:10.1142/s2737416526501036

BibTeX
@article{Muhammad2026,
  author = {Muhammad, Naveed and Rehman, Sehrish and Rauf, Abdur and Rashid, Umer and Khan, Muhammad Umer and Javaid, Fariha and Lodhi, Arif and Munir, Maha and Khan, Haroon and Al-Awthan, Yahya S. and Bahattab, Omar S. and Saleem, Muhammad and Goud, Pavan and Thiruvengadam, Muthu},
  title = {Acetylcholinesterase Inhibitory Potential and ADMET Analysis and Molecular Docking Studies of Coumarin and Benzohydrazide Derivatives in Alzheimer’s Disease},
  journal = {Journal of Computational Biophysics and Chemistry},
  year = {2026},
  pages = {1--18},
  doi = {10.1142/s2737416526501036}
}
Kostenlos starten →